Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$8.32
-1.0%
$6.89
$2.23
$9.52
$392.30M2.93655,614 shs574,133 shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$28.42
-0.9%
$21.03
$13.22
$42.57
$1.65B-1.651.04 million shs703,277 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$27.05
+1.7%
$33.63
$26.26
$41.61
$1.53B0.791.09 million shs1.13 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$37.62
-0.4%
$35.06
$16.16
$41.57
$1.53B0.83301,827 shs209,912 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-1.75%+0.60%+15.54%+99.05%-15.75%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
+5.13%+13.36%+29.89%+53.04%-33.29%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-2.53%-3.80%-26.12%-18.81%-23.15%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.38%-3.47%-4.21%+25.46%+77.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$8.32
-1.0%
$6.89
$2.23
$9.52
$392.30M2.93655,614 shs574,133 shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$28.42
-0.9%
$21.03
$13.22
$42.57
$1.65B-1.651.04 million shs703,277 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$27.05
+1.7%
$33.63
$26.26
$41.61
$1.53B0.791.09 million shs1.13 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$37.62
-0.4%
$35.06
$16.16
$41.57
$1.53B0.83301,827 shs209,912 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-1.75%+0.60%+15.54%+99.05%-15.75%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
+5.13%+13.36%+29.89%+53.04%-33.29%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-2.53%-3.80%-26.12%-18.81%-23.15%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.38%-3.47%-4.21%+25.46%+77.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.55
Moderate Buy$30.40265.38% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.89
Moderate Buy$68.67141.61% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
2.91
Moderate Buy$45.5068.21% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.13
Hold$28.40-24.51% Downside

Current Analyst Ratings Breakdown

Latest FDMT, GPCR, HRMY, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
9/27/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/25/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $35.00
9/25/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$54.00 ➝ $36.00
9/25/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$70.00 ➝ $55.00
9/24/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$48.00 ➝ $41.00
9/13/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/8/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K9,713.60N/AN/A$11.05 per share0.75
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$15.10 per shareN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$714.73M2.18$3.00 per share9.02$11.56 per share2.34
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.18$3.25 per share11.56$7.05 per share5.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$145.49M$3.108.738.700.3323.44%26.34%17.71%11/4/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$1.1831.8817.911.143.73%32.14%6.89%11/5/2025 (Estimated)

Latest FDMT, GPCR, HRMY, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.83N/AN/AN/AN/AN/A
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.57+$0.05$0.42$362.24 million$378.70 million
8/11/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million
8/6/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28-$0.36-$0.08-$0.36N/AN/A
8/5/2025Q2 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.78$0.68-$0.10$0.68$204.37 million$200.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.28%N/A40.68%N/A

Latest FDMT, GPCR, HRMY, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.26%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
8.75
8.75
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
20.48
20.48
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.20
3.84
3.80
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.46
2.76
1.25

Institutional Ownership

CompanyInstitutional Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.70 million42.22 millionOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.60 million54.37 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.53 million43.96 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.21 millionOptionable

Recent News About These Companies

New Strong Buy Stocks for October 7th
Best Income Stocks to Buy for October 7th
New Strong Buy Stocks for September 30th

New MarketBeat Followers Over Time

Media Sentiment Over Time

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$8.32 -0.08 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$8.32 -0.01 (-0.06%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$28.42 -0.26 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$28.01 -0.41 (-1.44%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$27.05 +0.46 (+1.73%)
Closing price 04:00 PM Eastern
Extended Trading
$27.35 +0.30 (+1.11%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$37.62 -0.17 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$37.60 -0.02 (-0.07%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.